IK-175 is under clinical development by Ikena Oncology and currently in Phase I for Colon Cancer. According to GlobalData, Phase I drugs for Colon Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the IK-175 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IK-175 overview

IK-175 (KYN-175) is under development for the treatment of locally advanced or metastatic solid tumors including bladder cancer, recurrent head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer, ovarian cancer, colon cancer, pancreatic cancer and urothelial carcinoma. It is administered by oral route. The drug candidate acts by targeting aryl hydrocarbon receptor (AHR) through Indoleamine 2, 3-dioxygenase (IDO)/ tryptophan 2, 3-dioxygenase (TDO) pathway.

Ikena Oncology overview

Ikena Oncology, formerly Kyn Therapeutics is a health care provider. The company is advancing novel immunometabolic therapies for the treatment of cancers. Its pipeline development programs include EP4 antagonist IK-007, which promotes immune suppression across a diverse range of immune cells; AHR antagonist, prevent AHR-modulated tumor promotion; and IK-412, a kynurenine-degrading enzyme (Kynase) that targets implicated in immunosuppression across a range of tumor types through multiple immune cell effects. Its immunosuppressive pathway inhibits the IDO and TDO pathway, enabling the body’s immune system to attack the tumor. Ikena Oncology is headquartered in Boston, Massachusetts, the US.

For a complete picture of IK-175’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.